• 1. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 2. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

Professional Introduction to 9,11-Anhydro-12-hydroxy Fusidic Acid (CAS No. 74048-44-5)

9,11-Anhydro-12-hydroxy Fusidic Acid is a significant compound in the field of pharmaceutical chemistry, renowned for its unique structural properties and therapeutic applications. With a CAS number of 74048-44-5, this compound has garnered considerable attention due to its role in the development of novel antibiotics and its potential in addressing resistant bacterial infections. This introduction delves into the compound's chemical characteristics, pharmacological significance, and the latest research findings that underscore its importance in modern medicine.

The molecular structure of 9,11-Anhydro-12-hydroxy Fusidic Acid is characterized by a complex lactone ring system, which is central to its biological activity. This structural motif imparts a high degree of specificity, enabling the compound to interact selectively with bacterial enzymes involved in protein synthesis. The presence of hydroxyl and anhydride functional groups further enhances its reactivity and binding affinity, making it an effective agent against a range of bacterial pathogens.

In recent years, the study of 9,11-Anhydro-12-hydroxy Fusidic Acid has been complemented by advancements in synthetic chemistry. Researchers have developed innovative methodologies to optimize the synthesis of this compound, improving yield and purity while reducing environmental impact. These advancements are crucial for ensuring a sustainable supply of the compound for pharmaceutical use.

The pharmacological profile of 9,11-Anhydro-12-hydroxy Fusidic Acid is particularly noteworthy for its mechanism of action. Unlike many traditional antibiotics that target bacterial cell wall synthesis or DNA replication, this compound inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This selective targeting minimizes side effects on human cells and reduces the likelihood of developing resistance mechanisms in bacteria.

Recent clinical trials have highlighted the efficacy of derivatives of 9,11-Anhydro-12-hydroxy Fusidic Acid in treating multidrug-resistant bacterial infections. These studies demonstrate that modifications to the core structure can enhance potency and broaden the spectrum of activity against various pathogens. Such findings are pivotal for addressing the growing global challenge of antibiotic resistance.

The role of 9,11-Anhydro-12-hydroxy Fusidic Acid in combinatorial therapy is another area of active research. By pairing this compound with other antibiotics or antiviral agents, researchers aim to develop synergistic treatments that can overcome resistance mechanisms more effectively. This approach holds promise for treating complex infections that require multiple therapeutic strategies.

From a chemical biology perspective, 9,11-Anhydro-12-hydroxy Fusidic Acid serves as a valuable scaffold for drug discovery. Its unique structural features allow chemists to design analogs with enhanced properties such as improved solubility, bioavailability, and metabolic stability. These efforts are essential for developing next-generation antibiotics that can meet the demands of contemporary healthcare challenges.

The environmental impact of synthesizing and using 9,11-Anhydro-12-hydroxy Fusidic Acid is also a critical consideration. Sustainable practices in production, such as green chemistry principles and biocatalysis, are being explored to minimize waste and energy consumption. These initiatives align with global efforts to promote environmentally responsible pharmaceutical manufacturing.

In conclusion, 9,11-Anhydro-12-hydroxy Fusidic Acid (CAS No. 74048-44-5) represents a cornerstone in modern antibiotic development. Its unique chemical properties and therapeutic potential make it indispensable in addressing bacterial infections worldwide. As research continues to uncover new applications and refine synthetic methodologies, this compound will undoubtedly play an even greater role in advancing healthcare solutions.

• 546-43-0(Alantolactone)
• 79233-15-1(Deoxyandrographolide)
• 6990-06-3(Fusidic acid)
• 470-17-7(Isoalantolactone)
• 16711-91-4(11-Keto Fusidic Acid)
• 136040-43-2(Schisanlactone E)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)